{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:12:19Z","timestamp":1791994339468,"version":"4.4.0"},"reference-count":41,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T00:00:00Z","timestamp":1488758400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Actinic keratoses (AKs) are intraepithelial atypical proliferations of keratinocytes that develop in skin that has undergone long\u2010term exposure to ultraviolet radiation. Given the ageing population and an increasing prevalence of AK, the socio\u2010economic burden of AK is likely to rise over the coming years. Areas of subclinical (non\u2010visible) sun damage in the periphery of visible AK lesions contain the same genetic changes as those found in the lesions themselves, and are known as areas of field cancerization. AK lesions and the field are associated with an increased risk of skin cancer, including invasive squamous cell carcinoma. Although effective in clearing visible AK, lesion\u2010directed therapies do not address field cancerization and can lead to high recurrence rates. In contrast, field\u2010directed therapies, such as ingenol mebutate, imiquimod and diclofenac, can clear both visible and subclinical AK lesions and reduce the development of new lesions in the treated field. Additionally, preclinical studies suggest that field therapy may prevent or delay the recurrence of non\u2010melanoma skin cancer. AK treatment guidelines now recognize the importance of treating the field in patients with AK, and adaptation of treatment guidelines into clinical practice is warranted. Physician and patient education around the consequences of leaving the field of cancerization untreated is necessary in order to reduce the increasing burden associated with AK.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.14092","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T06:50:31Z","timestamp":1488783031000},"page":"8-11","source":"Crossref","is-referenced-by-count":81,"title":["The importance of treating the field in actinic keratosis"],"prefix":"10.1111","volume":"31","author":[{"given":"E.","family":"Stockfleth","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Dermatologie, Venerologie und Allergologie St. Josef\u2010Hospital Ruhr\u2010Universit\u00e4t Bochum Bochum Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,6]]},"reference":[{"issue":"1","key":"e_1_2_6_2_1","first-page":"3","article-title":"Actinic keratosis and field cancerisation","volume":"21","author":"Stockfleth E","year":"2011","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962012000300012"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12434"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.103339"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/120347540200600301"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S9910"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1998.00467.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.1995.tb00141.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.146.s61.6.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.378"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.134"},{"issue":"2","key":"e_1_2_6_13_1","first-page":"8","article-title":"A survey of office visits for actinic keratosis as reported by NAMCS, 1990\u20101999. National Ambulatory Medical Care Survey.","volume":"70","author":"Gupta AK","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1990.tb124456.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03541.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.6.722"},{"key":"e_1_2_6_17_1","first-page":"S2","article-title":"Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach","volume":"7","author":"Rosso JQ","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-015-0070-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.11.037"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12016"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.14025"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.22.10124"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2013.11.013"},{"key":"e_1_2_6_25_1","first-page":"3604","article-title":"p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization","volume":"55","author":"Kanjilal S","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000254893"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11202.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12833"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.716039"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.001"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02056.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08271.x"},{"issue":"4","key":"e_1_2_6_33_1","first-page":"1","article-title":"Effects of ingenol mebutate 0.05% gel for the treatment of actinic field cancerization including subclinical actinic keratoses \u2013 assessment by reflectance confocal microscopy","volume":"171","author":"Ulrich M","year":"2014","journal-title":"Br J Dermatol"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.2174\/1872213X11307020008"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000370148"},{"key":"e_1_2_6_36_1","first-page":"92","article-title":"Evaluation of Ingenol mebutate efficacy for the treatment of actinic keratosis with Antera 3D camera","volume":"19","author":"Cantisani C","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_6_37_1","first-page":"741","article-title":"Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12\u2010month results","volume":"13","author":"Berman B","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.418"},{"key":"e_1_2_6_39_1","first-page":"w14026","article-title":"Swiss clinical practice guidelines on field cancerization of the skin","volume":"144","author":"Hofbauer G","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13180"},{"key":"e_1_2_6_41_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1684\/ejd.2014.2265","article-title":"Reduction in lesions from Lmax: a new concept for assessing efficacy of field\u2010directed therapy for actinic keratosis. Results with imiquimod 3.75%","volume":"24","author":"Stockfleth E","year":"2014","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12530"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T10:44:36Z","timestamp":1694515476000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":41,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/jdv.14092"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14092","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}